Unfortunately, infectious endocarditis (IE) will never go away. If anything, increased screening and the advent of transcatheter therapies for structural heart disease result in a higher number of cardiac implants, presumably increasing the absolute number of IE proportionally [ ]. While there have not been any specific advances in the treatment armamentarium for IE over the last decade, multiple societal guidelines have been released and changed with each iteration, primarily reflecting the uncertainty that persists surrounding a topic lacking high-quality evidence and the resulting differences in the interpretation of existing literature [ ].